Daniel Dongjune Shin, MD
Infectious Disease · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 3 carriers
- Offices
- 4
Offices
4 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: 757662 · El Camino Health. That is not proof they admit you there this week.
Plans that list them
5 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shin’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A72218 · Current
Licensed to practise in California · since 2000 · expires 2028-06-30 · Loyola University of Chicago Stritch School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$67,133
Medicare paid this office $67,133 for 226 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 127 | $31,722 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $11,965 | $153 |
| Return visit (30+ min) | 42 | $7,504 | $109 |
| Long return visit (40+ min) | 31 | $7,439 | $155 |
| New patient visit (60+ min) | 23 | $4,512 | $196 |
Who their Medicare patients are
226 Original Medicare patients in 2024. Average age 77 · Under 65 8% · 85 and older 24% · Women 46% · Also on Medicaid 20% · Health risk score 2.45. At or below the middle of the specialty; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Coronary heart disease 44% · Chronic kidney disease 39% · Atrial fibrillation 39% · Diabetes 38% · Heart failure 35% · COPD 32% · Depression 27% · Dementia 23% · Cancer 22% · Stroke 15%.
The office billed $243,819, Medicare allowed $86,655 and paid $67,133; for 554 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 226 | 554 | 77 | 2.45 | $243,819 | $67,133 |
| 2023 | 228 | 606 | 77 | 2.45 | $264,623 | $75,791 |
| 2022 | 201 | 817 | 76 | 2.85 | $301,569 | $84,741 |
| 2021 | 230 | 613 | 76 | 2.65 | $241,938 | $71,520 |
| 2020 | 237 | 960 | 75 | 2.89 | $283,209 | $93,213 |
| 2019 | 240 | 762 | 75 | 2.89 | $267,154 | $75,951 |
| 2018 | 206 | 627 | 75 | 2.88 | $212,481 | $62,913 |
| 2017 | 198 | 688 | 75 | 2.83 | $223,473 | $66,913 |
| 2016 | 195 | 760 | 74 | 2.49 | $231,647 | $69,639 |
| 2015 | 197 | 745 | 74 | 2.51 | $220,563 | $71,976 |
| 2014 | 218 | 879 | 74 | 2.55 | $263,181 | $79,024 |
| 2013 | 195 | 737 | 73 | 2.49 | $228,536 | $66,996 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 131 | $37,110 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $14,953 | $161 |
| Return visit (30+ min) | 50 | $9,510 | $115 |
| Long return visit (40+ min) | 36 | $6,665 | $159 |
| New patient visit (60+ min) | 31 | $5,974 | $193 |
2022: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 122 | $45,495 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 80 | $16,246 | $185 |
| Return visit (30+ min) | 49 | $10,455 | $110 |
| New patient visit (60+ min) | 22 | $4,489 | $204 |
| Long return visit (40+ min) | 20 | $3,681 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,345 | $67 |
2021: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 112 | $25,817 | $100 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 108 | $20,801 | $187 |
| Return visit (30+ min) | 43 | $8,808 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $5,662 | $69 |
| New patient visit (60+ min) | 17 | $3,421 | $201 |
| Long return visit (40+ min) | 16 | $3,056 | $153 |
| Short return visit (20+ min) | 11 | $992 | $76 |
2020: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 105 | $36,288 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 116 | $25,065 | $199 |
| Return visit (30+ min) | 49 | $10,001 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 82 | $9,957 | $72 |
| New patient visit (60+ min) | 21 | $4,025 | $192 |
2019: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 119 | $28,678 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 102 | $19,213 | $178 |
| Return visit (30+ min) | 61 | $9,811 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 75 | $8,151 | $64 |
| New patient visit (60+ min) | 23 | $4,011 | $174 |
| Long return visit (40+ min) | 16 | $2,227 | $106 |
| Hospital discharge day management, 30 minutes or less | 12 | $724 | $60 |
2018: 7 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 79 | $15,754 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $13,177 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 87 | $11,109 | $64 |
| Return visit (30+ min) | 62 | $11,078 | $93 |
| Long return visit (40+ min) | 29 | $4,904 | $123 |
| New patient visit (60+ min) | 18 | $3,158 | $175 |
| Short return visit (20+ min) | 12 | $971 | $61 |
2017: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 100 | $17,683 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 82 | $14,863 | $179 |
| Return visit (30+ min) | 52 | $10,632 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $8,787 | $92 |
| Long return visit (40+ min) | 38 | $8,531 | $127 |
| New patient visit (60+ min) | 19 | $3,615 | $190 |
2016: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 105 | $21,152 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 80 | $14,939 | $178 |
| Return visit (30+ min) | 49 | $9,401 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $8,557 | $92 |
| Long return visit (40+ min) | 33 | $7,489 | $121 |
| New patient visit (60+ min) | 22 | $4,006 | $182 |
| Short return visit (20+ min) | 15 | $1,270 | $67 |
2015: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 129 | $24,652 | $68 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 80 | $16,065 | $189 |
| Return visit (30+ min) | 51 | $12,291 | $102 |
| Long return visit (40+ min) | 29 | $6,636 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $6,340 | $98 |
| New patient visit (60+ min) | 13 | $2,435 | $187 |
2014: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 140 | $28,871 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $17,990 | $180 |
| Return visit (30+ min) | 49 | $10,102 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $9,151 | $92 |
| Long return visit (40+ min) | 32 | $5,770 | $128 |
| New patient visit (60+ min) | 14 | $2,638 | $188 |
| Short return visit (20+ min) | 17 | $1,430 | $65 |
2013: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 101 | $18,956 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 82 | $15,670 | $174 |
| Return visit (30+ min) | 63 | $11,943 | $93 |
| Long return visit (40+ min) | 24 | $5,068 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $4,760 | $90 |
| New patient visit (60+ min) | 22 | $3,952 | $180 |
| Short return visit (20+ min) | 18 | $1,764 | $63 |
Medicaid work
$906 in 2023
Medicaid paid $906 for 35 billed services this clinician did in 2023, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 35 | $906 |
| 2023 | 35 | 1 | 13 | $906 |
| 2021 | 98 | 1 | 15 | $10,282 |
| 2020 | 24 | 1 | 14 | $472 |
| 2019 | 44 | 2 | 13 | $1,538 |
| 2018 | 53 | 2 | 14 | $1,189 |
See the largest Medicaid services in earlier years
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 98 | $10,282 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 24 | $472 |
2019
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 32 | $1,100 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 12 | $438 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 39 | $919 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 14 | $271 |
Drugs they prescribed that Part D paid
$773,570
Pharmacies billed $773,570 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
490 generic and 203 brand-name prescriptions · $773,570 in drug cost · 266 antibiotic prescriptions to 73 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Biktarvy | None | 63 | $271,204 | $4,305 |
| Descovy | None | 41 | $102,740 | $2,506 |
| Gammaked | Immune globulin | 12 | $93,186 | $7,766 |
| Tivicay | None | 22 | $60,530 | $2,751 |
| Juluca | None | 13 | $52,992 | $4,076 |
See all 24 drugs
| Biktarvy | None | 63 | $271,204 | $4,305 |
| Descovy | None | 41 | $102,740 | $2,506 |
| Gammaked | Immune globulin | 12 | $93,186 | $7,766 |
| Tivicay | None | 22 | $60,530 | $2,751 |
| Juluca | None | 13 | $52,992 | $4,076 |
| Isentress | None | 13 | $29,596 | $2,277 |
| Maraviroc | None | 13 | $13,283 | $1,022 |
| Rifabutin | None | 20 | $8,209 | $410 |
| Posaconazole | None | 17 | $6,486 | $382 |
| Vancomycin | None | 21 | $5,176 | $246 |
| Ertapenem | None | 14 | $3,337 | $238 |
| Fluconazole | None | 17 | $1,308 | $77 |
| Ethambutol | None | 30 | $1,299 | $43 |
| Lamivudine Hbv | None | 11 | $558 | $51 |
| Amoxicillin-Clavulanate Potass | None | 18 | $440 | $24 |
| Cefazolin | None | 11 | $423 | $38 |
| Sulfamethoxazole-Trimethoprim | None | 25 | $390 | $16 |
| Levofloxacin | None | 34 | $384 | $11 |
| Ceftriaxone | None | 20 | $354 | $18 |
| Doxycycline Hyclate | None | 16 | $310 | $19 |
| Azithromycin | None | 19 | $221 | $12 |
| Cephalexin | None | 18 | $156 | $9 |
| Mirtazapine | None | 14 | $100 | $7 |
| Metformin | None | 15 | $31 | $2 |
Year by year
| 2024 | 693 | 107 | None | 29% | $773,570 |
| 2023 | 604 | 104 | None | None | $504,878 |
| 2022 | 573 | 90 | None | None | $388,734 |
| 2021 | 531 | 85 | None | 20% | $235,313 |
| 2020 | 547 | 79 | None | 12% | $271,954 |
| 2019 | 427 | 72 | None | None | $135,993 |
| 2018 | 439 | 84 | None | 18% | $171,684 |
| 2017 | 461 | 70 | None | 14% | $176,505 |
| 2016 | 606 | 67 | 5% (27) | 12% | $134,239 |
| 2015 | 523 | 65 | 6% (32) | 10% | $120,055 |
| 2014 | 458 | 63 | 4% (19) | 16% | $133,937 |
| 2013 | 447 | 61 | 6% (28) | 19% | $111,710 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Biktarvy | None | 39 | $183,860 | $4,714 |
| Gammaked | Immune globulin | 12 | $88,467 | $7,372 |
| Juluca | None | 13 | $47,013 | $3,616 |
| Descovy | None | 19 | $44,766 | $2,356 |
| Tivicay | None | 15 | $33,298 | $2,220 |
| Isentress | None | 12 | $25,683 | $2,140 |
| Maraviroc | None | 12 | $15,878 | $1,323 |
| Fluconazole | None | 18 | $3,864 | $215 |
| Rifampin | None | 29 | $3,829 | $132 |
| Abacavir | None | 11 | $3,746 | $341 |
| Vancomycin | None | 18 | $2,892 | $161 |
| Azithromycin | None | 26 | $2,632 | $101 |
| Ethambutol | None | 33 | $1,439 | $44 |
| Sulfamethoxazole-Trimethoprim | None | 22 | $771 | $35 |
| Ceftriaxone | None | 29 | $731 | $25 |
| Ampicillin-Sulbactam | None | 15 | $721 | $48 |
| Cefazolin | None | 18 | $698 | $39 |
| Lamivudine Hbv | None | 12 | $631 | $53 |
| Doxycycline Hyclate | None | 15 | $563 | $38 |
| Levofloxacin | None | 15 | $379 | $25 |
| Mirtazapine | None | 12 | $130 | $11 |
| Isoniazid | None | 21 | $125 | $6 |
2022: 13 drugs
| Biktarvy | 24 | $88,593 | $3,691 |
| Descovy | 23 | $51,126 | $2,223 |
| Moxifloxacin | 13 | $6,023 | $463 |
| Fluconazole | 26 | $4,718 | $181 |
| Cefepime | 19 | $4,668 | $246 |
| Ceftriaxone | 41 | $3,877 | $95 |
| Rifampin | 35 | $2,851 | $81 |
| Vancomycin | 16 | $2,725 | $170 |
| Azithromycin | 32 | $2,591 | $81 |
| Ethambutol | 49 | $1,975 | $40 |
| Doxycycline Hyclate | 11 | $549 | $50 |
| Amoxicillin-Clavulanate Potass | 12 | $402 | $33 |
| Sulfamethoxazole-Trimethoprim | 19 | $321 | $17 |
2021: 13 drugs
| Biktarvy | 21 | $72,395 | $3,447 |
| Rifampin | 42 | $4,481 | $107 |
| Fluconazole | 23 | $4,195 | $182 |
| Micafungin | 13 | $2,461 | $189 |
| Fosfomycin Tromethamine | 12 | $2,425 | $202 |
| Meropenem | 13 | $1,745 | $134 |
| Minocycline | 15 | $1,681 | $112 |
| Clindamycin | 24 | $1,244 | $52 |
| Ampicillin | 14 | $1,123 | $80 |
| Ethambutol | 35 | $1,012 | $29 |
| Azithromycin | 37 | $646 | $17 |
| Cefazolin | 11 | $569 | $52 |
| Sulfamethoxazole-Trimethoprim | 15 | $393 | $26 |
2020: 17 drugs
| Biktarvy | 25 | $82,777 | $3,311 |
| Daptomycin | 16 | $51,469 | $3,217 |
| Cefepime | 18 | $12,330 | $685 |
| Ceftriaxone | 19 | $5,737 | $302 |
| Fluconazole | 37 | $5,400 | $146 |
| Rifampin | 45 | $4,197 | $93 |
| Minocycline | 36 | $3,379 | $94 |
| Ampicillin-Sulbactam | 29 | $3,350 | $116 |
| Vancomycin | 13 | $2,032 | $156 |
| Ethambutol | 34 | $1,265 | $37 |
| Sulfamethoxazole-Trimethoprim | 14 | $1,177 | $84 |
| Doxycycline Hyclate | 21 | $1,094 | $52 |
| Clindamycin | 15 | $1,059 | $71 |
| Azithromycin | 21 | $907 | $43 |
| Ondansetron Odt | 15 | $478 | $32 |
| Cephalexin | 11 | $120 | $11 |
| Isoniazid | 12 | $87 | $7 |
2019: 11 drugs
| Biktarvy | 21 | $66,521 | $3,168 |
| Rifampin | 54 | $4,196 | $78 |
| Fluconazole | 22 | $3,995 | $182 |
| Ampicillin-Sulbactam | 30 | $2,920 | $97 |
| Minocycline | 36 | $2,669 | $74 |
| Doxycycline Hyclate | 18 | $1,641 | $91 |
| Clindamycin | 11 | $813 | $74 |
| Azithromycin | 11 | $800 | $73 |
| Amoxicillin-Clavulanate Potass | 12 | $417 | $35 |
| Sulfamethoxazole-Trimethoprim | 16 | $293 | $18 |
| Isoniazid | 12 | $69 | $6 |
2018: 11 drugs
| Vancomycin | 12 | $3,715 | $310 |
| Rifampin | 34 | $3,493 | $103 |
| Fluconazole | 16 | $3,004 | $188 |
| Ethambutol | 30 | $2,384 | $79 |
| Doxycycline Hyclate | 11 | $1,764 | $160 |
| Meropenem | 14 | $1,754 | $125 |
| Azithromycin | 22 | $1,238 | $56 |
| Amoxicillin-Clavulanate Potass | 16 | $903 | $56 |
| Ceftriaxone | 17 | $889 | $52 |
| Cefazolin | 11 | $701 | $64 |
| Isoniazid | 12 | $70 | $6 |
2017: 13 drugs
| Atripla | 14 | $36,449 | $2,603 |
| Ampicillin-Sulbactam | 22 | $5,575 | $253 |
| Rifampin | 46 | $3,765 | $82 |
| Ethambutol | 42 | $2,896 | $69 |
| Ampicillin | 24 | $2,563 | $107 |
| Azithromycin | 34 | $1,397 | $41 |
| Ceftriaxone | 22 | $1,080 | $49 |
| Doxycycline Hyclate | 11 | $475 | $43 |
| Amoxicillin-Clavulanate Potass | 11 | $461 | $42 |
| Prednisone | 17 | $208 | $12 |
| Sodium Chloride | 13 | $204 | $16 |
| Isoniazid | 13 | $76 | $6 |
| Furosemide | 11 | $24 | $2 |
2016: 20 drugs
| Atripla | 11 | $31,219 | $2,838 |
| Colcrys | 13 | $5,236 | $403 |
| Fluconazole | 13 | $2,988 | $230 |
| Rifampin | 40 | $2,792 | $70 |
| Ethambutol | 42 | $2,342 | $56 |
| Morphine Sulfate Er | 11 | $1,585 | $144 |
| Azithromycin | 22 | $1,411 | $64 |
| Levofloxacin | 15 | $1,409 | $94 |
| Amoxicillin-Clavulanate Potass | 32 | $1,304 | $41 |
| Moxifloxacin | 11 | $1,028 | $93 |
| Dapsone | 13 | $863 | $66 |
| Mirtazapine | 20 | $702 | $35 |
| Doxycycline Hyclate | 11 | $280 | $25 |
| Prednisone | 20 | $253 | $13 |
| Sulfamethoxazole-Trimethoprim | 15 | $219 | $15 |
| Isoniazid | 17 | $118 | $7 |
| Alendronate | 13 | $91 | $7 |
| Amoxicillin | 11 | $75 | $7 |
| Amlodipine Besylate | 11 | $67 | $6 |
| Furosemide | 18 | $23 | $1 |
2015: 17 drugs
| Vancomycin | 30 | $10,645 | $355 |
| Rifabutin | 12 | $8,696 | $725 |
| Colcrys | 12 | $4,241 | $353 |
| Ampicillin | 13 | $3,503 | $269 |
| Ceftriaxone | 19 | $3,461 | $182 |
| Rifampin | 33 | $3,001 | $91 |
| Ethambutol | 31 | $2,447 | $79 |
| Moxifloxacin | 15 | $1,531 | $102 |
| Amoxicillin-Clavulanate Potass | 31 | $1,224 | $39 |
| Clarithromycin | 12 | $1,018 | $85 |
| Azithromycin | 17 | $972 | $57 |
| Morphine Sulfate Er | 11 | $675 | $61 |
| Hydromorphone | 11 | $453 | $41 |
| Pantoprazole | 13 | $349 | $27 |
| Prednisone | 25 | $276 | $11 |
| Sulfamethoxazole-Trimethoprim | 18 | $129 | $7 |
| Isoniazid | 14 | $106 | $8 |
2014: 12 drugs
| Cubicin | 17 | $42,062 | $2,474 |
| Rifampin | 27 | $4,303 | $159 |
| Vancomycin | 14 | $3,229 | $231 |
| Ethambutol | 35 | $3,095 | $88 |
| Ampicillin | 18 | $3,034 | $169 |
| Ceftriaxone | 13 | $3,007 | $231 |
| Azithromycin | 18 | $1,558 | $87 |
| Clarithromycin | 11 | $1,155 | $105 |
| Ciprofloxacin | 15 | $650 | $43 |
| Amox Tr-Potassium Clavulanate | 16 | $460 | $29 |
| Sulfamethoxazole-Trimethoprim | 15 | $189 | $13 |
| Isoniazid | 25 | $150 | $6 |
2013: 12 drugs
| Piperacillin-Tazobactam | 34 | $9,361 | $275 |
| Epivir Hbv | 12 | $4,987 | $416 |
| Rifampin | 12 | $1,865 | $155 |
| Ethambutol | 11 | $1,321 | $120 |
| Azithromycin | 18 | $1,166 | $65 |
| Vancomycin | 11 | $967 | $88 |
| Amox Tr-Potassium Clavulanate | 13 | $692 | $53 |
| Sulfamethoxazole-Trimethoprim | 30 | $511 | $17 |
| Minocycline | 24 | $400 | $17 |
| Sodium Chloride | 25 | $391 | $16 |
| Fluconazole | 12 | $381 | $32 |
| Acyclovir | 21 | $328 | $16 |
Money from drug and device companies
$12 in 2025
| 2025 | 1 | 1 | None | $12 |
| 2022 | 1 | 1 | None | $26 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | None | $12 | 1 payment
|
See the published payment
| Gilead Sciences | Education · 2025-11-18 | None | $12 |
See earlier years (2022)
2022: $26
| Amgen | Lumakras | $26 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Gilead Sciences, Inc. · The Simple Study - Subjects With Mild To Moderate Coronavirus Infection · 2020 | Their institution | $39,249 |
| Gilead Sciences, Inc. · The Simple Study - Subjects With Mild To Moderate Coronavirus Infection · 2021 | Their institution | $21,864 |
| Gilead Sciences, Inc. · A Phase 1b/2a Study in A Phase 1b/2a Study in Participants With Early Stage Covid-19 To Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered By Inhalation · 2021 | Their institution | $19,949 |
| Gilead Sciences, Inc. · The Simple Study in Coronavirus, Severe Subjects · 2021 | Their institution | $19,744 |
| Gilead Sciences, Inc. · The Simple Study in Coronavirus, Severe Subjects · 2020 | Their institution | $9,261 |
Professional record
- NPI
- 1427065960
- Licence
- CA A72218California A72218: Current · expires 2028-06-30
- Trained
- Loyola University of Chicago, Stritch School of Medicine, 1995
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X)
- Mailing address
- 2350 W El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2006-08-01
- NPI last updated
- 2012-01-06
This is when the NPI record was last certified, not a medical board exam.